Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics granted 380,575 inducement stock options, including 275,000 to its new Chief Legal Officer, at a $23.42 exercise price.

Rhea-AI Summary

Bicara Therapeutics (BCAX) granted inducement stock options on September 1, 2026 to two new employees under its 2026 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received non-qualified options to purchase an aggregate of 380,575 common shares, including 275,000 options granted to newly appointed Chief Legal Officer Gregory Shiferman. The options have an exercise price of $23.42 per share, equal to the September 1, 2026 Nasdaq closing price. One-fourth of each award vests on the first anniversary of the employee’s start date, with the remainder vesting in 12 equal quarterly installments, subject to continued service. These options were issued outside stockholder-approved equity plans under the board-adopted 2026 Inducement Plan and approved by the compensation committee of independent directors.

News Explained

The disclosure describes rights to purchase shares, so any change in employee ownership is conditional on vesting, continued service, and exercise rather than occurring at the grant date.

Market Context

BCAX's prior daily close was $23.56 before this announcement. That pre-publication reference helps s...

Analysis

BCAX's prior daily close was $23.56 before this announcement. That pre-publication reference helps separate the equity-inducement disclosure from subsequent interpretation; recent insider activity was classified as Net Selling, while the grant's vesting terms and Nasdaq basis remain factual details to monitor.

Key Figures

Aggregate stock options: 380,575 shares Chief legal officer option grant: 275,000 shares Exercise price: $23.42 per share +4 more

7 metrics

Aggregate stock options 380,575 shares Two new employees; granted September 1, 2026

Chief legal officer option grant 275,000 shares Included within aggregate inducement grants

Exercise price $23.42 per share Equal to Nasdaq closing price on September 1, 2026

Common stock par value $0.0001 per share Bicara common stock

Initial vesting One-fourth of options Vests on the first anniversary of the applicable start date

Remaining vesting 12 equal quarterly installments Subject to continued service

Listing rule Nasdaq Listing Rule 5635(c)(4) Inducement grants issued outside stockholder-approved plans

Historical Context

5 past events · Latest: Aug 14 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 14	Inducement grant	Neutral	+2.8%	Grant to newly appointed chief financial officer under the inducement plan
Aug 11	Earnings leadership update	Negative	-14.2%	Quarterly loss and leadership transitions accompanied clinical development updates
Aug 04	Earnings date notice	Neutral	+1.4%	Company scheduled second-quarter financial results and business updates
Jul 28	Board appointments	Positive	-3.3%	Two directors with biotechnology and commercial experience joined the board
Jul 02	Inducement grants	Neutral	+0.3%	New employees received stock options under the inducement plan

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Reactions were mixed: the two prior inducement-grant announcements were followed by gains, while a leadership-and-results update and board appointments were followed by declines.

Key Terms

non-qualified stock options, par value, vesting, nasdaq listing rule 5635(c)(4)

4 terms

non-qualified stock options financial

"The employees received, in the aggregate, non-qualified stock options"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

par value financial

"common stock, par value $0.0001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

vesting financial

"the remaining options vest in 12 equal quarterly installments thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on September 1, 2026 to two new employees as a material inducement to employment under Bicara’s 2026 Inducement Plan.

The employees received, in the aggregate, non-qualified stock options to purchase 380,575 shares of Bicara’s common stock, par value $0.0001 per share, inclusive of a non-qualified stock option to purchase 275,000 shares of Bicara’s common stock granted to the Company’s newly appointed Chief Legal Officer, Gregory Shiferman. These awards were issued with an exercise price of $23.42 per share, equal to the closing price of Bicara’s common stock as reported by Nasdaq on September 1, 2026. One-fourth of the options vest on the first anniversary of the employee’s applicable start date, with the remaining options vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued service with the company through each applicable vesting date.

All of the above-described awards were granted outside of Bicara’s stockholder-approved equity incentive plans and are pursuant to Bicara’s 2026 Inducement Plan, which was adopted by Bicara’s board of directors in January 2026. The awards were approved by the compensation committee of Bicara’s board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn and X.

Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Dan Budwick
dan@1abmedia.com

FAQ

What inducement stock option grants did Bicara Therapeutics (BCAX) announce on September 3, 2026?

Bicara Therapeutics announced non-qualified stock option inducement grants for two new employees covering an aggregate of 380,575 common shares. The grants were made on September 1, 2026 under Bicara’s 2026 Inducement Plan as a material inducement to their employment.

How many Bicara Therapeutics (BCAX) stock options were granted to the new Chief Legal Officer?

The newly appointed Chief Legal Officer, Gregory Shiferman, received a non-qualified stock option to purchase 275,000 shares of Bicara’s common stock. This award is part of the total 380,575 inducement options granted on September 1, 2026.

What is the exercise price of the Bicara Therapeutics (BCAX) inducement options granted in September 2026?

The inducement stock options were issued with an exercise price of $23.42 per share. This price equals the closing price of Bicara’s common stock as reported by Nasdaq on September 1, 2026.

How do the Bicara Therapeutics (BCAX) inducement stock options vest for the new employees?

One-fourth of each employee’s options vest on the first anniversary of the applicable start date. The remaining options vest in 12 equal quarterly installments thereafter, subject to the employee’s continued service with Bicara through each vesting date.

Were the September 2026 Bicara Therapeutics (BCAX) inducement grants made under stockholder-approved plans?

No. The awards were granted outside Bicara’s stockholder-approved equity incentive plans. They were issued under Bicara’s 2026 Inducement Plan, adopted by the board in January 2026, and approved by the compensation committee of independent directors.